



Wellmark Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association.

DRUG POLICY

Antidepressant Drug Policy

NOTICE

This policy contains information which is clinical in nature. The policy is not medical advice. The information in this policy is used by Wellmark to make determinations whether medical treatment is covered under the terms of a Wellmark member's health benefit plan. Physicians and other health care providers are responsible for medical advice and treatment. If you have specific health care needs, you should consult an appropriate health care professional. If you would like to request an accessible version of this document, please contact customer service at 800-524-9242.

BENEFIT APPLICATION

Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions may apply. Benefits may vary based on contract, and individual member benefits must be verified. Wellmark determines medical necessity only if the benefit exists and no contract exclusions are applicable. This policy may not apply to FEP. Benefits are determined by the Federal Employee Program.

DESCRIPTION

The intent of the Antidepressant Drug Policy is to ensure appropriate selection of patients for treatment according to product labeling and/or clinical studies and/or guidelines, and to encourage use of more cost-effective generic immediate release agents prior to the use of a generic or brand name delayed release agent, a brand name immediate release agent, or a more costly generic.

POLICY

Criteria for Initial Approval

- I. Khedezla (brand and generic) and Desvenlafaxine fumarate ER may be considered **medically necessary** for the treatment of depression when all of the following criteria are met:
 - Patient has a diagnosis of major depressive disorder (MDD)
 - Patient must have had a therapeutic failure to ALL of the following unless the patient is currently receiving a positive therapeutic outcome on the requested medications through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs):
 - i. Extended-release venlafaxine at a maximally tolerated therapeutic dose for a minimum duration of 2 months
 - ii. One generic selective serotonin reuptake inhibitor (SSRI) at a maximally tolerated therapeutic dose for a minimum duration of 2 months OR the patient has experienced the same intolerable side effect with more than one SSRI trial, deemed a class effect of SSRI medication
 - iii. One alternative treatment strategy (bupropion, mirtazapine, trazodone, lithium, or another augmentation agent) at a maximally tolerated therapeutic dose for a minimum duration of 2 months

- Quantity request must not exceed 30 tablets per month

Approval will be for lifetime

- II. Viibryd and Fetzima may be considered **medically necessary** for the treatment of depression when all of the following criteria are met:
- Patient has a diagnosis of major depressive disorder (MDD)
 - Patient must have had a therapeutic failure to ALL of the following unless the patient is currently receiving a positive therapeutic outcome on the requested medications through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs):
 - i. One generic selective serotonin reuptake inhibitors (SSRI) at maximally tolerated therapeutic dose for a minimum duration of 2 months OR the patient has experienced the same intolerable side effect with more than one SSRI trial, deemed a class effect of SSRI medication
 - ii. One generic serotonin norepinephrine reuptake inhibitor (SNRI) at a maximally tolerated therapeutic dose for a minimum duration of 2 months OR the patient has experienced an intolerable side effect with more than one SNRI trial
 - iii. One alternative treatment strategy (bupropion, mirtazapine, trazodone, lithium, or another augmentation agent) at a maximally tolerated therapeutic dose for a minimum duration of 2 months

Approval will be for lifetime

- III. Pexeva may be considered **medically necessary** when all of the following criteria are met:
- Patient must have at least one of the following diagnoses:
 - i. Major Depressive Disorder (MDD)
 - ii. Generalized Anxiety Disorder (GAD)
 - iii. Obsessive Compulsive Disorder (OCD)
 - iv. Panic Disorder
 - Patient must have had a therapeutic failure to ALL of the following unless the patient is currently receiving a positive therapeutic outcome on Pexeva through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs):
 - i. Generic paroxetine for at least 2 months at a maximally tolerated therapeutic dose
 - ii. One selective serotonin reuptake inhibitor (SSRI), other than generic paroxetine, for at least 2 months at a maximally tolerated therapeutic dose
 - iii. One generic serotonin norepinephrine reuptake inhibitor (SNRI) for at least 2 months at a maximally tolerated therapeutic dose OR the patient has experienced an intolerable side effect with more than one SNRI trial.

Approval will be for lifetime

- IV. Luvox CR and generic equivalent may be considered **medically necessary** for the treatment of obsessive-compulsive disorder (OCD) when the following criteria is met:
- Member must have tried and failed TWO generic selective serotonin reuptake inhibitors (SSRI), one of which was the immediate release Luvox (fluvoxamine) at maximally tolerated therapeutic doses for a minimum duration of 2 months each unless the patient is currently receiving a positive therapeutic outcome on the requested medications through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs):

Approval will be for lifetime

- V. Trintellix may be considered **medically necessary** for the treatment of depression when all of the following criteria are met:
- Patient has a diagnosis of major depressive disorder (MDD)
 - Patient must have had a therapeutic failure to ALL of the following unless the patient is currently receiving a positive therapeutic outcome on Trintellix through health insurance (excludes obtainment as samples or via manufacturer's patient assistance programs):
 - i. Two generic selective serotonin reuptake inhibitors (SSRI) at maximally tolerated therapeutic doses for a minimum duration of 2 months each OR the patient has experienced the same intolerable side effect with more than one SSRI trial, deemed a class effect of SSRI medication..
 - ii. One generic serotonin norepinephrine reuptake inhibitor (SNRI) at a maximally tolerated therapeutic dose for a minimum duration of 2 months OR the patient has experienced an intolerable side effect with more than one SNRI trial.
 - iii. One alternative treatment strategy (bupropion, mirtazapine, trazodone, lithium, or another augmentation agent) at a maximally tolerated therapeutic dose for a minimum duration of 2 months.

Approval will be for lifetime

- VI. Khedezla (brand and generic), Desvenlafaxine fumarate ER, Viibryd, Fetzima, Pexeva, Luvox CR, and Trintellix are considered **not medically necessary** for patients who are started on therapy using "samples" (i.e. not a medication dispensed from the pharmacy or initiated during inpatient mental health hospitalization) without meeting the criteria set forth above.
- VII. Khedezla (brand and generic), Desvenlafaxine fumarate ER, Viibryd, Fetzima, Pexeva, Luvox CR, and Trintellix are considered **not medically necessary** for patients who do not meet the criteria set forth above.

Quantity Limits Apply

Desvenlafaxine ER 30 tablets/30 days, Desvenlafaxine Fumarate ER 30 tablets/30days, Fetzima 30 capsules/30days, Khedezla 30 tablets/30 days

PROCEDURES AND BILLING CODES

To report provider services, use appropriate CPT* codes, Alpha Numeric (HCPCS level 2) codes, Revenue codes, and/or ICD diagnostic codes.

- Code(s), if applicable.

REFERENCES

- Viibryd [*prescribing information*]. Irvine, CA: Allergan USA Inc., May 2018.
- Fetzima [*prescribing information*]. Irvine, CA: Allergan USA Inc., December 2017.
- Trintellix [*prescribing information*]. Deerfield, IL: Takeda Pharmaceuticals America, Inc., October 2018.
- Pexeva [*prescribing information*]. Miami, FL: Noven Therapeutics, LLC., July 2014.
- Luvox CR [*prescribing information*]. Palo Alto, CA: Jazz Pharmaceuticals, Inc., July 2014.
- Khedezla [*prescribing information*]. Spring Valley, NY: Par Pharmaceutical Cos., Inc., September 2013
- American Psychiatric Association Practice Guideline for the Treatment of patients with Major Depressive Disorder, 3rd edition. American Psychiatric Association; November 2010.

http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf accessed 6/18/19.

- Nelson JC, Pikalov, A, & Berman RM. Augmentation Treatment in Major Depressive Disorder: Focus on Aripiprazole. *Neuropsychiatric Disease and Treatment*. 2008;4(5): 937-248.
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. *N Engl J Med*. 2006;354(12):1243-52.
- Rush AJ; Trivedi MH; Stewart JW; et al. Combining Medication to Enhance Depression Outcomes (CO-MED): Acute and Long-Term Outcomes of Single-Blind Randomized Study. *AM J Psychiatry* 2011; 168:689-701.
- Amick HR, Gartlehner G, Gaynes BN et al. Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. *BMJ*. 2015; 351:h6019.
- Bauer M, Pfennig A, Severus E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. *World J Biol Psychiatry*. 2013; 14(5):334-85.
- Bauer M, Severus E, Kohler S et al.. Part 2: maintenance treatment of major depressive disorder – update 2015. URL: file:///C:/Users/u014934/Downloads/WFSBPPart2_Update2015.pdf. Available from Internet. Accessed 2019 January 25.
- Bschor T, Kern H, Henssler J et al. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. *J Clin Psychiatry*. 2018; 79(1).
- Gartlehner G, Gaynes BN, Amick HR et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. *Ann Intern Med*. 2016; 164(5):331-41.
- Henssler J, Bschor T, Baethge C. Combining antidepressants in acute treatment of depression: a meta-analysis of 38 studies including 4511 patients. *Can J Psychiatry*. 2016; 61(1):29-43.
- Henssler J, Kurschus M, Franklin J et al. Long-term acute-phase treatment with antidepressants, 8 weeks and beyond: a systematic review and meta-analysis of randomized, placebo-controlled trials. *J Clin Psychiatry*. 2018; 79(1).
- Ijaz S, Davies P, Williams CJ et al. Psychological therapies for treatment-resistant depression in adults. *Cochrane Database Syst Rev*. 2018; 5:CD010558.
- National Institute for Health and Care Excellence. Depression in children and young people: identification and management. 2019. Available at: <https://www.nice.org.uk/guidance/ng134/resources/depression-in-children-and-young-people-identification-and-management-pdf-66141719350981>. Accessed 9 June 2020.
- Cheung AH et al. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management. *PEDIATRICS*. 2018;141(3):1-16.
- Mahajan SS et al. Comparative Efficacy and Safety of Escitalopram versus Desvenlafaxine in Postmenopausal Women with Depression and Anxiety: A Randomized, Open-Label, Comparative Trial. *J Midlife Health*. 2019;10(3):141-146.
- Bathla M et al. A 12-week prospective randomized controlled comparative trial of vilazodone and sertraline in Indian patients with depression. *Indian J Pharmacol*. 2020;52(1):10-15.
- He H et al. Comparative Efficacy and Acceptability of First-Line Drugs for the Acute Treatment of Generalized Anxiety Disorder in Adults: A Network Meta-Analysis. *J Psychiatr Res*. 2019;118:21-30.
- Kotapati VP et al. The Effectiveness of Selective Serotonin Reuptake Inhibitors for Treatment of Obsessive-Compulsive Disorder in Adolescents and Children. A Systematic Review and Meta-Analysis. *Front Psychiatry*. 2019;10:523.

POLICY HISTORY

Policy #: 05.01.62

Policy Creation: May 2009

Revised: July 2018

Reviewed: July 2020

Current Effective Date: September 20, 2018